clinical trial · NCT06619561
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Deciphera Pharmaceuticals, LLC·phase2·recruiting·n = 48
Chronic Graft-Versus-Host Disease (cGVHD)Vimseltinib
brief summary
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
started
Nov 21, 2024
primary completion
Oct 1, 2029
completion
Oct 1, 2029
last updated
Dec 15, 2025
official title
A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol